Dr. Kuller is Professor, Division of Maternal-Fetal Medicine at Duke University, Durham, NC

Jeffrey A. Kuller, MD 

In the United States, the estimated prevalence of antenatal hepatitis C virus (HCV) infection is 1% to 4% in single-center studies.

 A national multicenter prospective cohort study estimated an HCV antibody seroprevalence of 0.24% among an obstetric population screened between 2012 and 2015.

The primary mode of HCV transmission is percutaneous exposure to blood from injection of illicit drugs. Other modes of transmission include sharing of contaminated devices for noninjection drug use, exposure to infected blood, and sexual intercourse.

 Vertical transmission is the leading cause of HCV infection in children.

HCV can cause both acute and chronic hepatitis. The first 6 months after exposure to HCV constitute the acute stage of infection 6. 

For the 25% of cases that are symptopatic, symptoms include abdominal pain, nausea, anorexia, jaundice, and malaise.

 Those who do not clear the virus and do not receive treatment will develop chronic HCV infection.

As with the acute stage of infection, chronic HCV infection is usually asymptomatic. Chronic infection accounts for most HCV-associated morbidity and mortality.

HCV infection is associated with higher rates of gestational diabetes, preterm birth, and low birth weight.

 However, these associations are often complicated by confounding factors such as maternal age, race, substance use, and prenatal care usage.

Antenatal testing is not indicated in the setting of HCV diagnosis alone (grade 2C).

Intrahepatic cholestasis of pregnancy (ICP) is more prevalent in patients with chronic HCV infection than in uninfected patients.

We suggest screening for viral hepatitis in patients with a diagnosis of ICP at an early gestational age or with significant elevations of bile acids (grade 2C).

We empirically suggest that this screening be performed if the diagnosis of ICP is made at less than 24 weeks of gestation or if bile acids are greater than or equal to 100 µmol/L.

Screening recommendations are changing to be more inclusive because of an increase in the prevalence of HCV infection among women of reproductive age and emerging data suggesting that the majority of neonates are not identified with the current risk-based screening strategies.

A recent cost-analysis model demonstrated that universal prenatal HCV screening improved health outcomes of people with HCV infection and identification of neonates with infection and was cost-effective, even in areas with very low prevalence.

The Centers for Disease Control and Prevention (CDC) now recommends universal screening for HCV during pregnancy.

 The United States Preventive Services Task Force (USPSTF) also recommends screening in all individuals ages 18 to 79 and specifically notes that pregnant women should be screened but does not recommend a frequency.

Early identification of HCV-positive patients during pregnancy can potentially facilitate more efficient linkage to care and treatment in the postpartum period because none of the antiviral therapies recommended for HCV infection are approved for use during pregnancy. 

We recommend that obstetric providers screen all pregnant patients for HCV by testing for anti-HCV antibodies in every pregnancy (grade 1B). 

Screening in the first trimester would theoretically identify the most patients at the earliest opportunity.

Diagnosis of HCV infection depends on the detection of anti-HCV antibodies and HCV RNA. Anti-HCV antibodies usually develop 2 to 6 months after exposure, during the acute phase of infection, and persist throughout life.

Liver function tests (AST, ALT, bilirubin)

HCV genotype (if not previously obtained)

STI screening (HIV, syphilis, gonorrhea, chlamydia, and HBV)

ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; STI, sexually transmitted infection.

HCV viremia or the presence of HCV RNA indicates active infection and can be detected 1 to 3 weeks after exposure.

we suggest that obstetric care providers screen HCV-positive pregnant patients for other sexually transmitted infections (if not done previously), including HIV, syphilis, gonorrhea, chlamydia, and hepatitis B virus (HBV) (grade 2C).

Pregnant patients with HCV should be screened for immunity to hepatitis A virus (HAV). 

We recommend vaccination against HAV and HBV (if not immune) for patients with HCV (grade 1B).

Among nonpregnant women, direct-acting antiviral (DAA) regimens are first-line treatments.

 Currently, none of the antiviral therapies recommended for HCV infection are approved for use during pregnancy.

Until more data exist, if a patient becomes pregnant while taking one of the DAA therapies, animal data do not suggest teratogenic risk but patients should be counseled that human data are lacking.

In these scenarios, shared decision-making regarding risks and benefits of cessation versus continuation should occur. 

We recommend that DAA regimens should be initiated only in the setting of a clinical trial during pregnancy and that individuals who become pregnant while taking a DAA should be counseled in a shared decision-making framework about the risks and benefits of continuation (grade 1C). 

Referral to a hepatologist or infectious disease specialist during pregnancy for patients with HCV may be considered to expedite therapy following pregnancy.

Amniocentesis does not appear to increase the risk of vertical transmission, although this conclusion is based on small sample sizes and limited data that have not addressed the potential impact of viral load.

No studies have been published on the risk of vertical transmission of HCV with other prenatal testing modalities, including chorionic villus sampling. 

We suggest that if prenatal diagnostic testing is requested, patients be counseled that data regarding the risk of vertical transmission are reassuring but limited (grade 2C). 

When the need or desire for diagnostic testing arises in patients with HCV, shared decision-making regarding the limited data should occur.

Vaginal delivery has not been shown to be a risk factor for vertical transmission of HCV.

 Because all published studies on the mode of delivery and the risk of vertical transmission of HCV are observational, and most did not assess viral load at the time of delivery, these results should be interpreted cautiously.

We recommend against cesarean delivery solely for the indication of HCV (grade 1B).

Several factors in labor management may be associated with an increased risk of vertical transmission of HCV, namely prolonged rupture of membranes, internal fetal monitoring, and episiotomy.

We suggest that obstetric care providers avoid internal fetal monitors and early artificial rupture of membranes when managing labor in patients with HCV,

unless necessary in the course of management (ie, when unable to trace the fetal heart rate with external monitors and the alternative is proceeding with cesarean delivery) (grade 2B).

Expectant management of ruptured membranes should be avoided at term. Usual obstetric management for preterm premature rupture of the membranes should not be altered because of maternal HCV infection. 

It is unclear whether a patient with a positive HCV antibody and a negative viral load should be managed in labor in the same fashion as one with a detectable viral load. 

We suggest that if the confirmatory HCV antibody test result were negative that the result be considered a false-positive; thus, the additional precautions suggested above are likely unnecessary. 

However, if the confirmatory test result is positive or if the test was not performed, then until further data are available, it may be safest in labor to follow the same suggestions as in a patient with a positive viral load because of the theoretical possibility of intermittent viral shedding.

Breastfeeding does not appear to affect the risk of vertical transmission of HCV.

We recommend that HCV status not alter standard breastfeeding counseling and recommendations unless nipples are cracked or bleeding (grade 1A).

 In patients with cracked or bleeding nipples, breast milk should be expressed and discarded. 

Prasad MR, Honegger JR. Hepatitis C virus in pregnancy. 

. 2013;30(2):149-159. doi:10.1055/s-0033-1334459

Prasad M, Saade GR, Sandoval G, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Hepatitis C virus antibody screening in a cohort of pregnant women: identifying seroprevalence and risk factors. 

. 2020;135(4):778-788. doi:10.1097/AOG.0000000000003754

HCV guidance: recommendations for testing, managing, and treating hepatitis C. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. Accessed January 10, 2021. 

T ohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? 

. 2010;52(4):1497-1505. doi:10.1002/hep.23808

Jhaveri R, Swamy GK. Hepatitis C virus in pregnancy and early childhood: current understanding and knowledge deficits. 

. 2014;3 Suppl 1(Suppl 1):S13-S18. doi:10.1093/jpids/piu045

Mok J, Pembrey L, Tovo PA, Newell ML; European Paediatric Hepatitis C Virus Network. When does mother to child transmission of hepatitis C virus occur? 

. 2005;90(2):F156-F160. doi:10.1136/adc.2004.059436

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. 

. 2007;110(4):941-956. doi:10.1097/01.AOG.0000263930.28382.2a

Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. 

. 2000;31(3):751-755. doi:10.1002/hep.510310328

Gervais A, Bacq Y, Bernuau J, et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. 

. 2000;32(2):293-299. doi:10.1016/s0168-8278(00)80075-6

Money D, Boucoiran I, Wagner E, et al. Obstetrical and neonatal outcomes among women infected with hepatitis C and their infants. 

. 2014;36(9):785-794. doi:10.1016/S1701-2163(15)30480-1

Paternoster DM, Santarossa C, Grella P, et al. Viral load in HCV RNA-positive pregnant women. 

. 2001;96(9):2751-2754. doi:10.1111/j.1572-0241.2001.04135.x

Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. 

. 2004;40(6):1426-1433. doi:10.1002/hep.20463

Fontaine H, Nalpas B, Carnot F, Bréchot C, Pol S. Effect of pregnancy on chronic hepatitis C: a case-control study. 

. 2000;356(9238):1328-1329. doi:10.1016/S0140-6736(00)02823-3

Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes. 

. 2011;31(8):1163-1170. doi:10.1111/j.1478-3231.2011.02556.x

Pergam SA, Wang CC, Gardella CM, Sandison TG, Phipps WT, Hawes SE. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. 

. 2008;199(1):38.e1-38.e9. doi:10.1016/j.ajog.2008.03.052

Smith DD, Rood KM. Intrahepatic cholestasis of pregnancy. 

. 2020;63(1):134-151. doi:10.1097/GRF.0000000000000495

Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. 

. 2014;124(1):120-133. doi:10.1097/AOG.0000000000000346

Delgado-Borrego A, Smith L, Jonas MM, et al. Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. 

. 2012;161(5):915-921. doi:10.1016/j.jpeds.2012.05.002

Rossi RM, Wolfe C, Brokamp R, et al. Reported prevalence of maternal hepatitis C virus infection in the United States. 

. 2020;135(2):387-395. doi:10.1097/AOG.0000000000003644

Sheffield JS, Argani CH. Hepatitis C virus infection in the pregnant woman: is it time for universal screening? 

. 2020;135(4):770-772. doi:10.1097/AOG.0000000000003815

Tasillo A, Eftekhari Yazdi G, Nolen S, et al. Short-term effects and long-term cost-effectiveness of universal hepatitis C testing in prenatal care. 

. 2019;133(2):289-300. doi:10.1097/AOG.0000000000003062

Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults - United States, 2020. 

. 2020;69(2):1-17. doi:10.15585/mmwr.rr6902a1

Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. 

. 2020;323(10):970-975. doi:10.1001/jama.2020.1123

Maheshwari A, Thuluvath PJ. Management of acute hepatitis C. 

. 2010;14(1):169-176; x. doi:10.1016/j.cld.2009.11.007

Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. 

Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. 

. 1998;27(6):1717-1722. doi:10.1002/hep.510270635

Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. 

. 2013;37(12):1132-1156. doi:10.1111/apt.12324

Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. 

Spera AM, Eldin TK, Tosone G, Orlando R. Antiviral therapy for hepatitis C: has anything changed for pregnant/lactating women? 

. 2016;8(12):557-565. doi:10.4254/wjh.v8.i12.557

Gagnon A, Davies G, Wilson RD; Genetics Committee. Prenatal invasive procedures in women with hepatitis B, hepatitis C, and/or human immunodeficiency virus infections. 

. 2014;36(7):648-653. doi:10.1016/S1701-2163(15)30546-6

Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. 

. 2013;158(2):109-113. doi:10.7326/0003-4819-158-2-201301150-0057532. 

Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV- mothers: a meta-analysis. 

. 2011;283(2):255-260. doi:10.1007/s00404-010-1588-9

McIntyre PG, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. 

. 2006;(4):CD005546. doi:10.1002/14651858.CD005546.pub2

European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. 

Garcia-Tejedor A, Maiques-Montesinos V, Diago-Almela VJ, et al. Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. 

. 2015;194:173-177. doi:10.1016/j.ejogrb.2015.09.009

Mast EE, Hwang LY, Seto DSY, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. 

. 2005;192(11):1880-1889. doi:10.1086/497701

Spencer JD, Latt N, Beeby PJ, et al. Transmission of hepatitis C virus to infants of human immunodeficiency virus–negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. 

. 1997;4(6):395-409. doi:10.1046/j.1365-2893.1997.00073.x

American Academy of Pediatrics. Hepatitis C. In: Kimberlin DW BM, Jackson MA, Long SS, eds. 

Red Book: 2018 Report of the Committee on Infectious Diseases

. American Academy of Pediatrics; 2018:428-434.

Articles

SMFM Consult Series #56: Hepatitis C in pregnancy: updated screening, treatment, and management guidelines. 

SMFM Consult Series #56: Hepatitis C in pregnancy: updated guidelines

In the United States, 1% to 2.5% of pregnant women are infected with hepatitis C virus (HCV), which carries an approximately 5% risk of transmission from mother to infant. HCV can be transmitted to an infant in utero or during the peripartum period. Two primary concerns arise from HCV in pregnancy: 1) maternal well-being, i.e., the effect of pregnancy on the course of chronic HCV infection; and 2) fetal well-being, namely mother-to-infant transmission of HCV and the impact of maternal infection on pregnancy outcomes. 

What is the natural course of HCV infection?

In addition to vertical transmission, HCV is transmitted through percutaneous exposure to blood through use of contaminated needles for injection of illicit drugs or during occupational exposure. Sexual intercourse is an inefficient means of transmission. The first 6 months after exposure to HCV is referred to as acute HCV infection, which is asymptomatic in 75% of cases. When symptoms occur, they include abdominal pain, nausea, anorexia, jaundice, or malaise. Without treatment, approximately 15% of infected individuals spontaneously clear HCV within 6 months of infection, although some estimate this number to be as high as 45%. Those who do not clear the virus harbor it for the rest of their lives and develop chronic HCV infection, which accounts for most HCV-associated morbidity and mortality, mainly due to cirrhosis and hepatocellular carcinoma.

Researchers speculate that down-regulation of the maternal immune response that occurs during pregnancy may reduce the amount of immune-mediated hepatocellular damage caused by HCV. This mechanism would also account for the decrease in alanine transaminase (ALT) levels seen in pregnant women with HCV and the increase in serum levels of HCV RNA during the second and third trimesters of pregnancy. Some histological evidence also suggests that pregnancy may be associated with a decrease in HCV-mediated hepatic injury, but data are conflicting.

What is the impact of HCV on pregnancy outcomes?

HCV infection is associated with adverse pregnancy outcomes. Two population-based, retrospective cohort studies and a recent meta-analysis found that infants born to women infected with HCV were more likely to have poor birth outcomes, including fetal growth restriction, low birth weight (LBW), and congenital anomalies, and to be delivered preterm. It is difficult to know with certainty whether the increased risk of adverse outcomes such as fetal growth restriction and LBW is due to the viral effect of HCV or to potential confounders in the population being studied.

In addition, several studies have reported higher rates of gestational diabetes in HCV-infected women compared with noninfected women, although in one of these studies, this association was limited to women with excessive weight gain during pregnancy. Another population-based, retrospective cohort study found that infants born to HCV-infected women were more likely to have feeding difficulties and other adverse neonatal outcomes, including cephalohematoma, brachial plexus injury, fetal distress, intraventricular hemorrhage, or neonatal seizures.

Intrahepatic cholestasis of pregnancy (ICP) has also been associated with HCV infection. The overall incidence of ICP in the general obstetric population is 0.2% to 2.5%, while the odds of developing ICP are 20-fold higher in HCV-infected pregnant women. Given the increased risk of fetal death associated with ICP, diagnosis of this disease in pregnant women is important.

Currently, a multicenter, prospective observational cohort study is underway to evaluate pregnancy outcomes in women with HCV. Outcomes being studied include preterm delivery, gestational diabetes, preeclampsia, cholestasis, and infant birth weight (Clinicaltrials.gov: NCT01959321).

What is the rate of vertical transmission of HCV?

Vertical transmission of HCV is the leading cause of HCV infection in children. While one-third to one-half of mother-to-child transmission of HCV appears to occur in utero prior to the last month of pregnancy, the remainder is thought to occur either in the last month of pregnancy or during delivery. In women who are coinfected with HIV and HCV, risk of vertical transmission is almost double that in women infected only with HCV.

In general, vertical transmission of HCV is thought to be a risk only for women with detectable HCV RNA during pregnancy. Whether the level of HCV viremia correlates with risk of transmission has yet to be determined. Several studies have shown that higher viral loads correlate with an increased risk of transmission, whereas other studies have failed to find such an association.

Who should be screened for HCV during pregnancy and what is the ideal screening test for HCV?

Current guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the Centers for Disease Control and Prevention (CDC) recommend risk-based screening for HCV in pregnant women. We recommend that obstetric care providers screen women who are at increased risk for HCV by testing for anti-HCV antibodies at their prenatal visit. If initial results are negative, HCV screening should be repeated later in pregnancy in women with persistent or new risk factors for HCV infection after their initial screening (e.g., new or ongoing use of injected or intranasal illicit drugs).

The standard screening test for HCV is an anti-HCV antibody test. Anti-HCV antibodies usually develop 2 to 6 months after exposure-during the acute phase of infection-and persist throughout life. A positive test result indicates one of the following: the patient has active HCV infection (acute or chronic), the patient had a past infection that has resolved, or the result is a false positive.

A positive anti-HCV antibody result should be followed by a quantitative nucleic acid test for HCV RNA. Diagnosis of HCV infection depends on detection of anti-HCV antibodies and HCV ribonucleic acid (RNA). HCV viremia, i.e., the presence of HCV RNA in the blood, indicates active infection and can first be detected 1 to 3 weeks after exposure.

What other additional evaluation should occur? 

For pregnant women with confirmed active HCV infection, a quantitative HCV RNA test should be done to determine baseline viral load. Basic laboratory testing to evaluate the extent of liver disease should include the following laboratory tests: bilirubin, ALT and aspartate aminotransferase (AST), albumin, platelet count, and prothrombin time. To help plan future treatment, testing for HCV genotype should also be performed (if not done previously).

In light of common risk factors, we recommend that obstetric care providers screen HCV-positive pregnant women for other sexually transmitted diseases, including HIV, syphilis, gonorrhea, chlamydia, and hepatitis B (HBV). Patients with HBV infection and a high viral load can be offered antenatal treatment; infants should receive the hepatitis B vaccine as well as hepatitis immune globulin. Hepatitis A virus (HAV) infection can also worsen hepatic damage if present with HCV infection. The Advisory Committee on Immunization Practices (ACIP) recommends that women with HCV infection who are found to be at risk of  HBV and/or HAV be vaccinated, and it is safe to do so during pregnancy.

Should HCV be treated pharmacologically during pregnancy?

Until 2011, the standard-of-care treatment for chronic HCV was pegylated interferon (PegIFN)-Î± and ribavirin. In 2011, direct-acting antiviral medications (DAAs) were released, revolutionizing treatment of HCV. These drugs directly inhibit proteins involved in HCV replication, have fewer side effects than interferon-based regimens, and have led to sustained virological response (SVR) rates as high as 60% to 100%. Treatment regimens usually involve multiple DAAs to prevent viral resistance. 

Because there are no adequate human data regarding any of the effects of second-generation DAAs in pregnancy, we recommend that DAA regimens only be used in the setting of a clinical trial or antiviral treatment should be deferred to the postpartum period as DAA regimens are not currently approved for use in pregnancy.

What are the principles of medical management of HCV during pregnancy?

Any woman who is diagnosed with HCV infection during pregnancy should be referred to a hepatologist or infectious disease specialist experienced in management of hepatitis in order to establish long-term care.

Use of even modest amounts of alcohol has been associated with progression of liver disease, and we suggest that patients with HCV, including pregnant women, be counseled to abstain from alcohol.

Serial laboratory surveillance of liver function or serial viral load assessment during pregnancy in HCV-positive women is generally not recommended. As discussed previously, serum levels of ALT tend to decrease during the second and third trimesters of pregnancy, i.e., liver function is expected to improve, not worsen, during pregnancy.

Is invasive prenatal diagnostic testing safe in pregnant women with HCV?

Amniocentesis does not appear to increase risk of vertical transmission, although this conclusion is based on limited data. No studies have been published on risk of vertical transmission of HCV with other invasive prenatal testing modalities, including chorionic villus sampling (CVS). We suggest that if invasive prenatal diagnostic testing is requested, women be counseled that data on the risk of vertical transmission are reassuring but limited; amniocentesis is recommended over CVS given lack of data on the latter.

Does mode of delivery affect risk of vertical transmission?

Mode of delivery-vaginal versus cesarean-has not been shown to be a risk factor for vertical transmission of HCV. However, because all published studies on mode of delivery and risk of vertical transmission of HCV are observational and most did not assess viral load at the time of delivery, these results should be interpreted cautiously. We recommend against cesarean delivery solely for the indication of HCV.

Does labor management affect risk of vertical transmission? 

Several factors in labor management may be associated with increased risk of vertical transmission of HCV, namely prolonged rupture of membranes, internal fetal monitoring, and episiotomy. Based on the available evidence, we recommend that obstetric care providers avoid internal fetal monitoring, prolonged rupture of membranes, and episiotomy in managing labor in HCV-positive women, unless it is unavoidable in the course of management. We also recommend that obstetric care providers avoid early amniotomy and episiotomy in managing labor in HCV-positive women.

Is breastfeeding safe for HCV-positive mothers?

Breastfeeding does not appear to affect the risk of vertical transmission of HCV. We recommend against discouraging breastfeeding based on a positive HCV infection status. If women have cracked and bleeding nipples, milk should be expressed and discarded.

How should infants born to HCV-positive women be screened for HCV infection?

Because anti-HCV antibodies can be transmitted across the placenta from a pregnant woman to the fetus, the presence of anti-HCV antibodies in a neonate’s serum soon after delivery is not diagnostic of neonatal infection. The American Academy of Pediatrics and CDC recommend screening of infants born to HCV-positive women for anti-HCV antibodies after age 18 months or for HCV RNA on two occasions in infants older than age 1 month.

In the United States, 1% to 2.5% of pregnant women are infected with hepatitis C virus (HCV), which carries an approximately 5% risk of transmission from mother to infant. HCV can be transmitted to an infant in utero or during the peripartum period.

Jeffrey A. Kuller, MD

Articles

SMFM Consult Series #56: Hepatitis C in pregnancy: updated guidelines

Hepatitis C in pregnancy: Screening, treatment, and management